China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre. COVID global emergency over but risks remain, says China health official (Reuters)…
China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…
China A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric cancer partnership with CARsgen; Sino Biopharm’s continued attempt to buyout of F-star Therapeutics and Takeda’s deal with Hutchmed for a…
China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals. Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…
China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics. Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…
Hong Kong After a record year of new biotech listings in 2021, the Hong Kong Stock Exchange (HKEX) has seen a significant drop-off in the first eight months of 2022. The exchange went from 20 new listings last year to only four this year, with just three full months of 2022 remaining…
Taiwan The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s Vaxxinity and the Phase II clinical trials completion for a Taiwanese COVID treatment. Bora consolidates its position in Taiwan’s…
Adl Biopharma ADL Biopharma is a Spanish CDMO and, according to its CEO, owner of Europe’s largest fermenter. Ignacio Urbelz, CEO, reveals how, after a tumultuous time that saw the company go bankrupt in 2013 and change ownership in 2020, the organization has reorganized with the intention of returning to its 1990s…
Switzerland In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and out-licensing deal for its head and neck cancer product; as well as a host of other topics, including the company’s…
Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…
Global To celebrate International Women’s Day 2020, PharmaBoardroom brings you insights from some of the most inspirational female industry leaders we have had the privilege of talking to over the past 12 months. Janet Woodcock, Director, Center for Drug Evaluation and Research (CDER), US FDA Science really can…
Taiwan United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform capabilities. Chang Yi Wang is the Chairperson and CSO of United BioPharma (UBP), a member of the UBI group of…
See our Cookie Privacy Policy Here